AUCATZYL Revenue Doubles to $41.2M; Full-Year Guidance Raised Above $150M
AUTL sits 16% above its 52-week low of $1.175 on elevated volume (2.2× avg).
Summary
Autolus posted Q3 2026 net product revenue of $41.2 million, roughly double the $21.1 million a year ago, and now expects full-year 2026 AUCATZYL revenue at or above the upper end of its prior $150 million guidance. Gross margin climbed to 57% from 55% in Q2 as manufacturing cost per batch fell, and the net loss narrowed to $55.1 million from $79.1 million. Cash and marketable securities stood at $248.4 million at September 30, which management says funds operations into Q2 2028, helped by the $100 million Perceptive credit facility. The miss is on the pipeline clock: first progressive MS data slipped to October 2027 from an earlier date, while lupus nephritis LUMINA data are not expected until 2028. Near-term news flow is the CARLYSLE lupus poster at ACR today and initial ALARIC light-chain amyloidosis data at ASH on December 12, 2026.
At the time of this announcement, AUTL was trading at $1.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $351.3M. The 52-week trading range was $1.18 to $2.58. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.